WASHINGTON — There is growing momentum for lawmakers to push forward with the CREATES Act — a long-stalled measure that proponents say will help bring generic drugs to market faster and lower drug prices — according to both supporters and opponents of the bill.

Part of that momentum comes as branded drug makers, who had initially pushed back on the legislation, have relaxed their outright opposition to the measure, according to lobbyists both for branded drug makers and for other industries that support the legislation.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy